Drug Sales Trends for SINGULAIR

Annual Sales Revenues and Units Sold for SINGULAIR

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
SINGULAIR			2021
SINGULAIR			2020
SINGULAIR			2019
SINGULAIR			2018

Montelukast Sodium (Singulair) Market Analysis and Sales Projections

Market Overview

Montelukast sodium, commonly known by the brand name Singulair, is a leukotriene receptor antagonist used primarily in the treatment of asthma and allergic rhinitis. The market for this medication is experiencing significant growth driven by several key factors.

Market Size and Growth Projections

• The global montelukast sodium market is estimated to be valued at USD 4.08 billion in 2024 and is projected to reach USD 7.38 billion by 2029, growing at a CAGR of 12.60% during the forecast period[1].
• Another projection indicates that the market will grow from USD 4.1 billion in 2023 to USD 7.1 billion by 2033, with a CAGR of 5.64% from 2023 to 2033[2].
• A more conservative estimate suggests the market will grow from USD 326.71 million in 2024 to USD 773.78 million by 2032, with a CAGR of 11.4% during this period[3].

Regional Market Analysis

• North America: This region holds the largest share of the montelukast sodium market, driven by factors such as a high prevalence of respiratory disorders, well-established healthcare infrastructure, and the widespread presence of retail pharmacies and drug stores. Approximately 25 million Americans have asthma, contributing significantly to the market size[4].
• Asia Pacific: This region is expected to be the fastest-growing market during the forecast period. The expanding geriatric population, particularly in countries like India and China, and the increasing pollution problems in these regions are key drivers of market growth[1][4].

Market Drivers

Rising Prevalence of Respiratory Disorders

The increasing global prevalence of asthma and other respiratory disorders is a significant driver of the montelukast sodium market. With rising pollution levels, changing lifestyles, and growing awareness of respiratory health, the demand for effective medications like montelukast sodium is on the rise[3].

Growing Geriatric Population

The aging population worldwide is more susceptible to respiratory illnesses, leading to an increased need for medications like montelukast sodium. By 2030, there will be 994 million older people globally, and by 2050, this number is expected to reach 1.6 billion, further boosting market growth[1].

Advancements in Healthcare Infrastructure

Improvements in healthcare infrastructure, especially in emerging economies, are expanding the accessibility of montelukast sodium. This, combined with increasing investments in research and development, is driving market expansion[3].

Self-Medication and Over-the-Counter Availability

The growing trend of self-medication and the over-the-counter availability of montelukast sodium in some regions are also contributing to market growth. As consumers become more proactive about managing their health, the demand for accessible and affordable medications like montelukast sodium is increasing[3].

Market Restraints

Side Effects

Despite the positive growth trends, the market faces restraints due to the side effects associated with montelukast sodium, such as stomach pain, heartburn, upset stomach, nausea, and diarrhea. These side effects can deter some patients from using the medication, potentially slowing market growth[1].

Market Segmentation

By Dosage Form

The pills/tablets segment is expected to be the fastest-growing, with a CAGR of 12.0% over the forecast period. This growth is due to the broadening demand from the geriatric population, high accuracy of pills, and low production costs for companies[4].

By Application

Montelukast sodium is used not only for asthma but also for treating allergic rhinitis and other respiratory conditions. The expanding use cases are contributing to the overall market growth[3].

By Region

The market is segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America currently holds the largest share, but the Asia-Pacific region is expected to grow the fastest during the forecast period[4].

Key Players

Major players in the montelukast sodium market include Sandoz International, Sun Pharmaceutical Industries, and Merck. These companies are continually investing in research and development to enhance the efficacy and patient compliance of montelukast sodium[3].

Clinical Significance and COVID-19 Impact

Montelukast sodium has shown clinical activity in patients with COVID-19, reducing instances of clinical deterioration. This has positively impacted the market, as it has been recommended as part of the treatment protocol for COVID-19 prognosis[1].

"Patients with COVID-19 who were hospitalized and given montelukast experienced fewer instances of clinical deterioration, suggesting that this medication may have clinical activity"[1].

Future Trends

• Increased Generic Competition: The expiration of patents and the entry of generic versions are expected to influence market dynamics, potentially reducing the market share of branded products[5].
• Shift Towards Combination Therapies: There is a growing trend towards combination therapies, which could impact the demand for montelukast sodium as a standalone treatment[5].
• Expansion in Emerging Markets: The focus on emerging markets, particularly in Asia-Pacific, is expected to drive growth due to improving healthcare infrastructure and increasing GDPs in these regions[3][4].
• Focus on Pediatric Use: There is an increasing focus on pediatric use, which could expand the market for montelukast sodium as it is used to treat asthma and allergic rhinitis in children[5].
• Digital Health Solutions: The integration of digital health solutions is expected to enhance patient compliance and monitoring, further driving market growth[5].

Key Takeaways

• The montelukast sodium market is projected to grow significantly, driven by the rising prevalence of respiratory disorders, an expanding geriatric population, and advancements in healthcare infrastructure.
• North America currently holds the largest market share, but the Asia-Pacific region is expected to be the fastest-growing.
• The market faces restraints due to side effects associated with the medication.
• Key players are investing in research and development to enhance the efficacy and patient compliance of montelukast sodium.
• Future trends include increased generic competition, a shift towards combination therapies, expansion in emerging markets, a focus on pediatric use, and the integration of digital health solutions.

FAQs

Q: What is the projected market size of montelukast sodium by 2029? A: The global montelukast sodium market is expected to reach USD 7.38 billion by 2029[1].

Q: Which region is expected to be the fastest-growing market for montelukast sodium? A: The Asia-Pacific region is expected to be the fastest-growing market during the forecast period[1][4].

Q: What are the primary drivers of the montelukast sodium market? A: The primary drivers include the rising prevalence of respiratory disorders, an expanding geriatric population, and advancements in healthcare infrastructure[1][3].

Q: What are the common side effects associated with montelukast sodium? A: Common side effects include stomach pain, heartburn, upset stomach, nausea, and diarrhea[1].

Q: How has COVID-19 impacted the montelukast sodium market? A: Montelukast sodium has shown clinical activity in patients with COVID-19, reducing instances of clinical deterioration, which has positively impacted the market[1].

Sources

1. Mordor Intelligence: Montelukast Sodium Market Size & Share Analysis - Growth Trends[1]
2. Spherical Insights: Global Montelukast Sodium Market Size, Forecast 2023 - 2033[2]
3. Polaris Market Research: Montelukast Sodium Market Share and Size, Future Growth 2024[3]
4. IndustryARC: Montelukast Sodium Market - Forecast(2024 - 2030)[4]
5. The Business Research Company: Montelukast Sodium Global Market Report 2024[5]